ArticleContemporary clinical trials communications2026
Progesterone in feminizing gender affirming hormone therapy: study protocol for a randomized placebo-controlled trial.
Article in Contemporary clinical trials communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06807580 (Effects of Oral Progesterone in Transgender Women on Breast Development, Sleep Quality, Psychological Distress, and Cardiovascular Risk), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Oral Progesterone in Transgender Women on Breast Development, Sleep Quality, Psychological Distress, and Cardiovascular Risk
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: Transgender women receiving feminizing hormone therapy increasingly request progesterone based on anecdotal reports of improved breast development, sleep, mood, and quality of life. However, evidence supporting progesterone as an adjunct to feminizing gender-affirming hormone therapy remains limited. Methods: This randomized, double-blind, placebo-controlled clinical trial will evaluate oral micronized progesterone 200 mg nightly versus matched placebo in transgender women aged 18-60 years who have been receiving stable feminizing hormone therapy for at least 6 months. Participants will be followed monthly for 6 months. Baseline assessments include blood pressure, height, weight, breast hemi-circumference, and validated questionnaires assessing psychological distress, sleep quality, and gender congruence/life satisfaction: the Kessler Psychological Distress Scale, Pittsburgh Sleep Quality Index, and Gender Congruence and Life Satisfaction Scale. Monthly visits will assess medication adherence, side effects, and adverse events. Questionnaires will be repeated at month 3 and month 6. The final visit will include repeat physical measurements, breast hemi-circumference, questionnaires, laboratory testing, and return of remaining study medication. The primary outcome is change in psychological distress at 6 months. Secondary outcomes include changes in sleep quality, gender congruence/life satisfaction, breast hemi-circumference, blood pressure, lipid measures, estradiol, creatinine, alanine aminotransferase, and aspartate aminotransferase. Adverse events will be summarized by treatment group. Discussion: This study will evaluate the role of oral micronized progesterone as an adjunct to standard feminizing hormone therapy. It is designed to assess physical and cardiometabolic outcomes, as well as adverse events, to inform the safety, feasibility, and potential clinical role of progesterone in transfeminine care. Trial registration: Registered in www.clinicaltrials.gov on January 29, 2025 with registration number NCT06807580. FDA IND #171225.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.